Fernanda G Herrera

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1429462/publications.pdf

Version: 2024-02-01

686830 580395 1,035 31 13 25 citations h-index g-index papers 31 31 31 1462 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Radiotherapy combination opportunities leveraging immunity for the next oncology practice. Ca-A Cancer Journal for Clinicians, 2017, 67, 65-85.	157.7	344
2	Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. Cancer Discovery, 2022, 12, 108-133.	7.7	165
3	Rational combinations of immunotherapy with radiotherapy in ovarian cancer. Lancet Oncology, The, 2019, 20, e417-e433.	5.1	89
4	The role of PET/CT in cervical cancer. Frontiers in Oncology, 2013, 3, 34.	1.3	68
5	[18F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy. Radiation Oncology, 2016, 11, 43.	1.2	49
6	[18F]FDG-PET Standard Uptake Value as a Metabolic Predictor of Bone Marrow Response toÂRadiation: Impact on Acute and Late Hematological Toxicity in Cervical Cancer Patients Treated With Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1099-1107.	0.4	42
7	Comparison of ultra-high versus conventional dose rate radiotherapy in a patient with cutaneous lymphoma. Radiotherapy and Oncology, 2022, 174, 87-91.	0.3	39
8	50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial. International Journal of Radiation Oncology Biology Physics, 2019, 103, 320-334.	0.4	28
9	Lighting up the tumor fire with low-dose irradiation. Trends in Immunology, 2022, 43, 173-179.	2.9	26
10	Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease. Journal of Clinical Oncology, 2021, 39, 3022-3033.	0.8	24
11	Novel inverse planning optimization algorithm for robotic radiosurgery: First clinical implementation and dosimetric evaluation. Physica Medica, 2019, 64, 230-237.	0.4	23
12	Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland. Strahlentherapie Und Onkologie, 2015, 191, 778-786.	1.0	18
13	Retrospective feasibility study of simultaneous integrated boost in cervical cancer using tomotherapy: the impact of organ motion and tumor regression. Radiation Oncology, 2013, 8, 5.	1.2	15
14	Salvage radiotherapy for macroscopic local recurrences after radical prostatectomy. Strahlentherapie Und Onkologie, 2018, 194, 9-16.	1.0	14
15	Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice. Radiation Oncology, 2019, 14, 177.	1.2	13
16	High versus low dose irradiation for tumor immune reprogramming. Current Opinion in Biotechnology, 2020, 65, 268-283.	3.3	13
17	Radiation Therapy after Radical Prostatectomy: Implications for Clinicians. Frontiers in Oncology, 2016, 6, 117.	1.3	10
18	Stereotactic Body Radiation Therapy in Patients with Oligometastatic Disease: Clinical State of the Art and Perspectives. Cancers, 2022, 14, 1152.	1.7	10

#	Article	IF	CITATIONS
19	Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab. Clinical and Translational Radiation Oncology, 2021, 27, 85-88.	0.9	8
20	Unsupervised Analysis of Flow Cytometry Data in a Clinical Setting Captures Cell Diversity and Allows Population Discovery. Frontiers in Immunology, 2021, 12, 633910.	2.2	8
21	Low-dose irradiation for reversing immunotherapy resistance: how to translate?., 2022, 10, e004939.		8
22	Long-term Outcome and Late Side Effects in Endometrial Cancer Patients Treated with Surgery and Postoperative Radiation Therapy. Annals of Surgical Oncology, 2014, 21, 2390-2397.	0.7	7
23	Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer. Frontiers in Immunology, 2022, 13, .	2.2	5
24	Active surveillance in males with low- to intermediate-risk localized prostate cancer: A modern prospective cohort study. Investigative and Clinical Urology, 2021, 62, 416.	1.0	3
25	Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC. Lancet Oncology, The, 2022, 23, e157.	5.1	2
26	SMARCA4-Deficient Carcinoma of Uterine Cervix Resembling SCCOHTâ€"Case Report. Pathology and Oncology Research, 2021, 27, 1610003.	0.9	2
27	Survival of the fetus: cervical cancer and pregnancy, a challenging combination. Lancet, The, 2020, 396, 725.	6.3	1
28	So-Called Serous Carcinoma of the Uterine Cervix with BRCA2 Mutation: Case Report and Review of the Literature. Case Reports in Oncology, 2022, 14, 1792-1798.	0.3	1
29	A new method to visualize and to spare the ureters during SBRT for oligo metastatic patients. Technical Innovations and Patient Support in Radiation Oncology, 2021, 19, 7-10.	0.6	0
30	A Locally Advanced Endometrioid Adenocarcinoma Arising from Vaginal Endometriosis: Management and Review of the Literature. Reports, 2021, 4, 29.	0.2	0
31	EORTC trial 22991: Results of a phase III study comparing 6 months of androgen suppression and irradiation versus irradiation alone for localized T1b-cT2aNOMO prostate cancer Journal of Clinical Oncology, 2016, 34, 22-22.	0.8	0